Oxaliplatine Accord 5 mg/ml concentraat voor oplossing voor infusie
Sponsors
AstraZeneca AB, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Catharina Ziekenhuis Stichting, Stichting Amsterdam UMC
Conditions
Advanced Biliary Tract CancersColorectal liver metastasesPancreatic cancerperitoneal dissemination in stomach cancer patients
Phase 2
Personalized dosing of FOLFIRINOX in pancreatic cancer patients: a phase-2 pharmacokinetic, safety and feasibility trial
RecruitingCTIS2024-510576-21-00
Start: 2024-09-18Target: 100Updated: 2024-07-09
Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; PERISCOPE-2
Active, not recruitingCTIS2023-510159-53-01
Start: 2017-09-28Target: 226Updated: 2025-01-22
Phase 3
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)
WithdrawnCTIS2022-502043-35-00
Target: 76Updated: 2023-09-04
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)
Active, not recruitingCTIS2022-502043-35-01
Start: 2024-04-24Target: 76Updated: 2025-11-26
COLLISION RELAPSE trial
Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvant systemic therapy, a phase III prospective randomized controlled trial
Not yet recruitingCTIS2024-515341-41-01
Target: 360Updated: 2024-12-11